Targeting angiogenesis in ovarian cancer

Cancer Treatment Reviews

Volumn 38, Issue 4, 2012, Pages 272-283

  Schmitt, Jordan ^a   Matei, Daniela ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Angiopoietin; Clinical trials; FGF; Ovarian cancer; PDGF; VEGF

Indexed keywords

AFLIBERCEPT; ANGIOPOIETIN; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB; CARBOPLATIN; CEDIRANIB; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOVITINIB; DOXORUBICIN; ERLOTINIB; GEMCITABINE; GW 78603; IMATINIB; IMC A1; LENVATINIB; NINTEDANIB; PACLITAXEL; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PRO 001; SORAFENIB; SUNITINIB; TOPOTECAN; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ACUTE KIDNEY FAILURE; AMINOTRANSFERASE BLOOD LEVEL; ANASARCA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTERY THROMBOSIS; ASCITES; AUTOPHOSPHORYLATION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CARBOXY TERMINAL SEQUENCE; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COMPETITIVE INHIBITION; CYTOPENIA; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIPLOPIA; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; EDEMA; EPITHELIAL MESENCHYMAL TRANSITION; FATIGUE; FEBRILE NEUTROPENIA; FISTULA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; LUNG TOXICITY; LYMPHANGIOGENESIS; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL EDEMA; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN TARGETING; PROTEINURIA; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISCOLORATION; THROMBOCYTOPENIA; THROMBOSIS; UPREGULATION;

ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS;

EID: 84859156536     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.06.004     Document Type: Review

References (172)

1. Folkman J., Watson K., Ingber D., Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339(6219):58-61.
2. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86(3):353-364.
3. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246(4935):1306-1309.
4. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989, 161(2):851-858.
5. Vincenti V., Cassano C., Rocchi M., Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996, 93(8):1493-1495.
6. Ferrara N., Houck K., Jakeman L., Leung D.W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrinol Rev 1992, 13(1):18-32.
7. Ferrara N. Vascular endothelial growth factor. Eur J Cancer 1996, 32A(14):2413-2422.
8. Joukov V., Pajusola K., Kaipainen A., et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996, 15(2):290-298.
9. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255(5047):989-991.
10. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8(8):579-591.
11. Jakeman L.B., Winer J., Bennett G.L., Altar C.A., Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 1992, 89(1):244-253.
12. Kumaran G.C., Jayson G.C., Clamp A.R. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009, 100(1):1-7.
13. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001, 7(5):575-583.
14. Yang S., Toy K., Ingle G., et al. Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol 2002, 22(11):1797-1803.
15. Kukk E., Lymboussaki A., Taira S., et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996, 122(12):3829-3837.
16. Eichmann A., Corbel C., Jaffredo T., et al. Avian VEGF-C: cloning, embryonic expression pattern and stimulation of the differentiation of VEGFR2-expressing endothelial cell precursors. Development 1998, 125(4):743-752.
17. Oh S.J., Jeltsch M.M., Birkenhager R., et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol 1997, 188(1):96-109.
18. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438(7070):967-974.
19. Burger R.A., Sill M.W., Monk B.J., Greer B.E., Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25(33):5165-5171.
20. Bamberger E.S., Perrett C.W. Angiogenesis in epithelian ovarian cancer. Mol Pathol 2002, 55(6):348-359.
21. Shen G.H., Ghazizadeh M., Kawanami O., et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000, 83(2):196-203.
22. Goodheart M.J., Ritchie J.M., Rose S.L., Fruehauf J.P., De Young B.R., Buller R.E. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res 2005, 11(10):3733-3742.
23. Hefler L.A., Mustea A., Konsgen D., et al. Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 2007, 13(3):898-901.
24. Abu-Jawdeh G.M., Faix J.D., Niloff J., et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996, 74(6):1105-1115.
25. Wong Te Fong G.S., Bamberger E.S., et al. Quantification of VEGF-A, PD-ECGF/TP in normal, benign, malignant ovarian lesions. Rev Oncol 2002, 4:122.
26. Hazelton D., Nicosia R.F., Nicosia S.V. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res 1999, 5(4):823-829.
27. Yamamoto S.K.I., Koruda H., et al. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res 2001, 5.
28. Folkman J. A new link in ovarian cancer angiogenesis: lysophosphatidic acid and vascular endothelial growth factor expression. J Natl Cancer Inst 2001, 93(10):734-735.
29. Tempfer C., Obermair A., Hefler L., Haeusler G., Gitsch G., Kainz C. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 1998, 92(3):360-363.
30. Osada R., Horiuchi A., Kikuchi N., et al. Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol 2006, 37(11):1414-1425.
31. Jeon B.H., Jang C., Han J., et al. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res 2008, 68(4):1100-1109.
32. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146(5):1029-1039.
33. Gullino P. Extracellular compartments of solid tumors, Cancer: a comprehensive treatise 1975, Plenum Press, [p. 327-354].
34. Mesiano S., Ferrara N., Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998, 153(4):1249-1256.
35. Byrne A.T., Ross L., Holash J., et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003, 9(15):5721-5728.
36. McClure N., Healy D.L., Rogers P.A., et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994, 344(8917):235-236.
37. Yao R., Cooper G.M. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science 1995, 267(5206):2003-2006.
38. Huang J.S., Huang S.S., Deuel T.F. Transforming protein of simian sarcoma virus stimulates autocrine growth of SSV-transformed cells through PDGF cell-surface receptors. Cell 1984, 39(1):79-87.
39. Yu J., Moon A., Kim H.R. Both platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta promote murine fibroblast cell migration. Biochem Biophys Res Commun 2001, 282(3):697-700.
40. Greenhalgh D.G., Sprugel K.H., Murray M.J., Ross R. PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol 1990, 136(6):1235-1246.
41. Antoniades H.N., Hunkapiller M.W. Human platelet-derived growth factor (PDGF): amino-terminal amino acid sequence. Science 1983, 220(4600):963-965.
42. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9(6):669-676.
43. Fredriksson L., Li H., Fieber C., Li X., Eriksson U. Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J 2004, 23(19):3793-3802.
44. Kazlauskas A., Cooper J.A. Autophosphorylation of the PDGF receptor in the kinase insert region regulates interactions with cell proteins. Cell 1989, 58(6):1121-1133.
45. Andrae J., Gallini R., Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008, 22(10):1276-1312.
46. Valius M., Kazlauskas A. Phospholipase C-gamma 1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal. Cell 1993, 73(2):321-334.
47. Heldin C.H., Ostman A., Ronnstrand L. Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta 1998, 1378(1):F79-F113.
48. Coughlin S.R., Escobedo J.A., Williams L.T. Role of phosphatidylinositol kinase in PDGF receptor signal transduction. Science 1989, 243(4895):1191-1194.
49. Rodriguez-Viciana P., Warne P.H., Dhand R., et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994, 370(6490):527-532.
50. Hu Q., Klippel A., Muslin A.J., Fantl W.J., Williams L.T. Ras-dependent induction of cellular responses by constitutively active phosphatidylinositol-3 kinase. Science 1995, 268(5207):100-102.
51. Ma D., Nutt C.L., Shanehsaz P., Peng X., Louis D.N., Kaetzel D.M. Autocrine platelet-derived growth factor-dependent gene expression in glioblastoma cells is mediated largely by activation of the transcription factor sterol regulatory element binding protein and is associated with altered genotype and patient survival in human brain tumors. Cancer Res 2005, 65(13):5523-5534.
52. Chen W.V., Delrow J., Corrin P.D., Frazier J.P., Soriano P. Identification and validation of PDGF transcriptional targets by microarray-coupled gene-trap mutagenesis. Nat Genet 2004, 36(3):304-312.
53. Auersperg N., Maines-Bandiera S.L., Dyck H.G., Kruk P.A. Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab Invest 1994, 71(4):510-518.
54. Matei D., Emerson R.E., Lai Y.C., et al. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 2006, 25(14):2060-2069.
55. Henriksen R., Funa K., Wilander E., Backstrom T., Ridderheim M., Oberg K. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 1993, 53(19):4550-4554.
56. Apte S.M., Bucana C.D., Killion J.J., Gershenson D.M., Fidler I.J. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol 2004, 93(1):78-86.
57. Lassus H., Sihto H., Leminen A., et al. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer 2004, 91(12):2048-2055.
58. Crickard K., Gross J.L., Crickard U., et al. Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol Oncol 1994, 55(2):277-284.
59. Valve E., Martikainen P., Seppanen J., et al. Expression of fibroblast growth factor (FGF)-8 isoforms and FGF receptors in human ovarian tumors. Int J Cancer 2000, 88(5):718-725.
60. Matei D., Chang D.D., Jeng M.H. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 2004, 10(2):681-690.
61. Matei D., Graeber T.G., Baldwin R.L., Karlan B.Y., Rao J., Chang D.D. Gene expression in epithelial ovarian carcinoma. Oncogene 2002, 21(41):6289-6298.
62. Schmandt R.E., Broaddus R., Lu K.H., et al. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 2003, 98(4):758-764.
63. Wilczynski S.P., Chen Y.Y., Chen W., Howell S.B., Shively J.E., Alberts D.S. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol 2005, 36(3):242-249.
64. Makela T.P., Alitalo R., Paulsson Y., Westermark B., Heldin C.H., Alitalo K. Regulation of platelet-derived growth factor gene expression by transforming growth factor beta and phorbol ester in human leukemia cell lines. Mol Cell Biol 1987, 7(10):3656-3662.
65. Forsberg K., Valyi-Nagy I., Heldin C.H., Herlyn M., Westermark B. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 1993, 90(2):393-397.
66. Pietras K., Pahler J., Bergers G., Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008, 5(1):e19.
67. Chen E.Y., Mazure N.M., Cooper J.A., Giaccia A.J. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res 2001, 61(6):2429-2433.
68. Erber R., Thurnher A., Katsen A.D., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004, 18(2):338-340.
69. Kourembanas S., Hannan R.L., Faller D.V. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells. J Clin Invest 1990, 86(2):670-674.
70. Wang D., Huang H.J., Kazlauskas A., Cavenee W.K. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res 1999, 59(7):1464-1472.
71. Cao R., Brakenhielm E., Li X., et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J 2002, 16(12):1575-1583.
72. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111(9):1287-1295.
73. Uren A., Yu J.C., Gholami N.S., Pierce J.H., Heidaran M.A. The alpha PDGFR tyrosine kinase mediates locomotion of two different cell types through chemotaxis and chemokinesis. Biochem Biophys Res Commun 1994, 204(2):628-634.
74. Barrett T.B., Seifert R.A., Bowen-Pope D.F. Regulation of platelet-derived growth factor receptor expression by cell context overrides regulation by cytokines. J Cell Physiol 1996, 169(1):126-138.
75. Pietras K., Rubin K., Sjoblom T., et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002, 62(19):5476-5484.
76. Papapetropoulos A., Fulton D., Mahboubi K., et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem 2000, 275(13):9102-9105.
77. Falcon B.L., Hashizume H., Koumoutsakos P., et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009, 175(5):2159-2170.
78. Suri C., Jones P.F., Patan S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87(7):1171-1180.
79. Oliner J., Min H., Leal J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6(5):507-516.
80. Zhang L., Yang N., Park J.W., et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003, 63(12):3403-3412.
81. Scharpfenecker M., Fiedler U., Reiss Y., Augustin H.G. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005, 118(Pt 4):771-780.
82. Teilmann S.C., Christensen S.T. Localization of the angiopoietin receptors Tie-1 and Tie-2 on the primary cilia in the female reproductive organs. Cell Biol Int 2005, 29(5):340-346.
83. Colvin J.S., Bohne B.A., Harding G.W., McEwen D.G., Ornitz D.M. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet 1996, 12(4):390-397.
84. Katoh M. Cancer genomics and genetics of FGFR2 (Review). Int J Oncol 2008, 33(2):233-237.
85. Zhang Y., Gorry M.C., Post J.C., Ehrlich G.D. Genomic organization of the human fibroblast growth factor receptor 2 (FGFR2) gene and comparative analysis of the human FGFR gene family. Gene 1999, 230(1):69-79.
86. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10(2):116-129.
87. Byron S.A., Gartside M.G., Wellens C.L., et al. FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol 2010, 117(1):125-129.
88. Carstens R.P., McKeehan W.L., Garcia-Blanco M.A. An intronic sequence element mediates both activation and repression of rat fibroblast growth factor receptor 2 pre-mRNA splicing. Mol Cell Biol 1998, 18(4):2205-2217.
89. Steele I.A., Edmondson R.J., Bulmer J.N., Bolger B.S., Leung H.Y., Davies B.R. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene 2001, 20(41):5878-5887.
90. Itoh N., Ornitz D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004, 20(11):563-569.
91. Birrer M.J., Johnson M.E., Hao K., et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 2007, 25(16):2281-2287.
92. Rosen A., Sevelda P., Klein M., et al. First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer. Br J Cancer 1993, 67(5):1122-1125.
93. Yoneda J., Kuniyasu H., Crispens M.A., Price J.E., Bucana C.D., Fidler I.J. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998, 90(6):447-454.
94. Sako A., Kitayama J., Yamaguchi H., et al. Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: possible role of mesothelial cell on the development of peritoneal metastasis. J Surg Res 2003, 115(1):113-120.
95. Barton D.P., Cai A., Wendt K., Young M., Gamero A., De C.S. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res 1997, 3(9):1579-1586.
96. Song S., Wientjes M.G., Gan Y., Au J.L. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000, 97(15):8658-8663.
97. Keyes K., Cox K., Treadway P., et al. An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res 2002, 62(19):5597-5602.
98. Gan Y., Wientjes M.G., Au J.L. Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res 2006, 23(6):1324-1331.
99. Cole C., Lau S., Backen A., et al. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol Ther 2010, 10(5):495-504.
100. Steele I.A., Edmondson R.J., Leung H.Y., Davies B.R. Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines. Growth Factors 2006, 24(1):45-53.
101. Czubayko F., Liaudet-Coopman E.D., Aigner A., Tuveson A.T., Berchem G.J., Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 1997, 3(10):1137-1140.
102. Schelling M.E. FGF mediation of coronary angiogenesis. Ann NY Acad Sci 1991, 638:467-469.
103. Jouanneau J., Moens G., Montesano R., Thiery J.P. FGF-1 but not FGF-4 secreted by carcinoma cells promotes in vitro and in vivo angiogenesis and rapid tumor proliferation. Growth Factors 1995, 12(1):37-47.
104. Seghezzi G., Patel S., Ren C.J., et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998, 141(7):1659-1673.
105. Akai J., Halley P.A., Storey K.G. FGF-dependent Notch signaling maintains the spinal cord stem zone. Genes Dev 2005, 19(23):2877-2887.
106. Hansson M., Olesen D.R., Peterslund J.M., et al. A late requirement for Wnt and FGF signaling during activin-induced formation of foregut endoderm from mouse embryonic stem cells. Dev Biol 2009, 330(2):286-304.
107. Harada H., Kettunen P., Jung H.S., Mustonen T., Wang Y.A., Thesleff I. Localization of putative stem cells in dental epithelium and their association with Notch and FGF signaling. J Cell Biol 1999, 147(1):105-120.
108. Ikeya T., Hayashi S. Interplay of Notch and FGF signaling restricts cell fate and MAPK activation in the Drosophila trachea. Development 1999, 126(20):4455-4463.
109. Kawakami Y., Capdevila J., Buscher D., Itoh T., Rodriguez E.C., Izpisua Belmonte J.C. WNT signals control FGF-dependent limb initiation and AER induction in the chick embryo. Cell 2001, 104(6):891-900.
110. Katoh M., Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007, 13(14):4042-4045.
111. Katoh M. Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev 2007, 3(1):30-38.
112. Matei D., Kelich S., Cao L., et al. PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther 2007, 6(12):1951-1959.
113. Blagden S., Gabra H. Promising molecular targets in ovarian cancer. Curr Opin Oncol 2009, 21(5):412-419.
114. Cannistra S.A., Matulonis U.A., Penson R.T., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007, 25(33):5180-5186.
115. Kaye S.B. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?. J Clin Oncol 2007, 25(33):5150-5152.
116. Colombo N., Mangili G., Mommoliti S., et al. Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: preliminary results of a pilot study. J Clin Oncol 2008, 26(15S).
117. Buchdunger E., Zimmermann J., Mett H., et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 1995, 92(7):2558-2562.
118. Buchdunger E., Zimmermann J., Mett H., et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996, 56(1):100-104.
119. Coleman R.L., Broaddus R.R., Bodurka D.C., et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006, 101(1):126-131.
120. Posadas E.M., Kwitkowski V., Kotz H.L., et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 2007, 110(2):309-317.
121. Schilder R.J., Sill M.W., Lee R.B., et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2008, 26(20):3418-3425.
122. Kantarjian H., Jabbour E., Grimley J., Kirkpatrick P. Dasatinib. Nat Rev Drug Discov 2006, 5(9):717-718.
123. Schittenhelm M.M., Shiraga S., Schroeder A., et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006, 66(1):473-481.
124. Hochhaus A., Kantarjian H.M., Baccarani M., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007, 109(6):2303-2309.
125. Cortes J., Rousselot P., Kim D.W., et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007, 109(8):3207-3213.
126. Matei D., Sill M.W., Lankes H.A., et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial. J Clin Oncol 2011, 29(1):69-75.
127. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24(26):4293-4300.
128. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24(16):2505-2512.
129. Biagi J.J., Oza A.M., Chalchal H.I., et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 2010.
130. Drevs J., Siegert P., Medinger M., et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007, 25(21):3045-3054.
131. Hirte H.W., Vidal L., Fleming G.F., et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. J Clin Oncol 2010, 26(15S).
132. Matulonis U.A., Berlin S.T., Krasner C.N., et al. Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol 2008, 26(15S).
133. Friedlander M., Hancock K.C., Beningno B., et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: results of a phase II study. Ann Oncol 2008, 19(Suppl. 8):Viii211.
134. Mross K., Stefanic M., Gmehling D., et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010, 16(1):311-319.
135. Okamoto I., Kaneda H., Satoh T., et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010, 9(10):2825-2833.
136. Ledermann JA, Rustin GJ, Hackshaw A, et al. A randomised phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer. Presented at: the 16th Biennial International Meeting of the European Society of Gynaecological Oncology; October 11-14, 2009; Belgrade, Serbia 2009;27(15S).
137. Berek J.S., Bertelsen K., du B.A., et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999, 10(Suppl. 1):87-92.
138. Thigpen J.T., Vance R.B., Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993, 71(4 Suppl):1559-1564.
139. Alberts D.S. Treatment of refractory and recurrent ovarian cancer. Semin Oncol 1999, 26(1 Suppl. 1):8-14.
140. Cannistra S.A., Bast R.C., Berek J.S., et al. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol 2003, 21(10 Suppl.):129s-132s.
141. Penson R.T., Dizon D.S., Cannistra S.A., et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2010, 28(1):154-159.
142. Burger R.A., Brady M.F., Bookman M.A., et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study. J Clin Oncol 2010, 28(7S).
143. Perren T., Swart A.M., Pfisterer J., et al. ICON7: A phase III randomised gynaecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol 2010, 21(Suppl. 8):Viii2-Viii3.
144. du Bois A., Huober J., Stopfer P., et al. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 2010, 21(2):370-375.
145. McGonigle K.F., Muntz H.G., Vuky J.L., et al. Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (OC). J Clin Oncol 2008, 26(15S).
146. Karlan B.Y., Ozra A.M., Hansen V.L., et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. J Clin Oncol 2010, 28(15s).
147. Matei D., Emerson R.E., Schilder J., et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 2008, 113(4):723-732.
148. Tillmanns T.D., Lowe M.P., Schwartzberg L.S., Walker M.S., Stepanski E.J. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol 2010, 28(7S).
149. Chiorean E.G., Matei D., Younger A., et al. Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors. J Clin Oncol 2010, 28(15s):3043.
150. Siu L.L., Awada A., Takimoto C.H., et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006, 12(1):144-151.
151. Welch S., Hirte H., Schilder R.J., et al. Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: a PMH phase II consortium trial. J Clin Oncol 2006, 24(18S).
152. Garcia A.A., Hirte H., Fleming G., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008, 26(1):76-82.
153. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001, 19(14):3312-3322.
154. Campos S. A Retrospective Analysis of the Clinical Utility of Doxil in Recurrent Ovarian Cancer. Proceedings of the American Society of Clinical Oncology. 1999.
155. Gordon A.N., Tonda M., Sun S., Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004, 95:1-8.
156. Ferrandina G., Ludovisi M., Lorusso D., et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008, 26(6):890-896.
157. Friberg G., Oza A.M., Morgan R.J., Vokes E.E., Gandara D.R., Fleming G.F. Bevacizumab (B) plus erlotinib (E) for patients (pts) with recurrent ovarian (OC) and fallopian tube (FT) cancer: preliminary results of a multi-center phase II trial. J Clin Oncol 2006, 24. (18S).
158. Azad N.S., Posadas E.M., Kwitkowski V.E., et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008, 26(22):3709-3714.
159. Bocci G., Man S., Green S.K., et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res 2004, 64(18):6616-6625.
160. Willett C.G., Duda D.G., di T.E., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009, 27(18):3020-3026.
161. Rafii S., Lyden D., Benezra R., Hattori K., Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat Rev Cancer 2002, 2(11):826-835.
162. Beaudry P., Force J., Naumov G.N., et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005, 11(9):3514-3522.
163. Willett C.G., Boucher Y., di T.E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10(2):145-147.
164. Jain R.K., Duda D.G., Clark J.W., Loeffler J.S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006, 3(1):24-40.
165. Laking G., Price P. Radionuclide imaging of perfusion and hypoxia. Eur J Nucl Med Mol Imaging 2010, 37(Suppl. 1):S20-S29.
166. Fraioli F., Anzidei M., Zaccagna F., et al. Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience. Radiology 2011.
167. Rieger J., Bahr O., Muller K., Franz K., Steinbach J., Hattingen E. Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 2010, 99(1):49-56.
168. Schneider B.P., Wang M., Radovich M., et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26(28):4672-4678.
169. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4(6):437-447.
170. Bacon A.L., Harris A.L. Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Ann Med 2004, 36(7):530-539.
171. Imai T., Horiuchi A., Wang C., et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol 2003, 163(4):1437-1447.
172. Krtolica A., Ludlow J.W. Hypoxia arrests ovarian carcinoma cell cycle progression, but invasion is unaffected. Cancer Res 1996, 56(5):1168-1173.